Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.
暂无分享,去创建一个
J. Haanen | P. Snaebjornsson | S. Wilgenhof | S. V. van Turenhout | J. V. van Dieren | J. Burgers | M. Berghuis
[1] A. Shinagare,et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor , 2019, Abdominal Radiology.
[2] Wei-min Li,et al. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials , 2018, Journal of Cancer Research and Clinical Oncology.
[3] M. Respondek,et al. Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease , 2018, Modern Pathology.
[4] D. Schadendorf,et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. , 2017, European journal of cancer.
[5] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] C. Langner,et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.
[7] A. Carneiro,et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis , 2017, Cancer Immunology, Immunotherapy.
[8] D. V. van Langenberg,et al. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis , 2016, Inflammatory bowel diseases.
[9] A. Pommer,et al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis , 2016, Oncoimmunology.
[10] Siddharth Singh,et al. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis , 2015, Inflammatory bowel diseases.
[11] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[12] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[13] Young Sook Park,et al. Long-Term Outcomes of Cytomegalovirus Reactivation in Patients with Moderate to Severe Ulcerative Colitis: A Multicenter Study , 2014, Gut and liver.
[14] Young Sook Park,et al. The Prevalence and Efficacy of Ganciclovir on Steroid-refractory Ulcerative Colitis With Cytomegalovirus Infection: A Prospective Multicenter Study , 2012, Journal of clinical gastroenterology.
[15] L. Peyrin-Biroulet,et al. Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative Colitis , 2011, The American Journal of Gastroenterology.
[16] H. Tilg,et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[17] H. Ogata,et al. Cytomegalovirus Is Frequently Reactivated and Disappears Without Antiviral Agents in Ulcerative Colitis Patients , 2007, The American Journal of Gastroenterology.
[18] A. Rizzo,et al. Severe acute colitis associated with CMV: a prevalence study. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.